Rima Kaddurah-Daouk
Rima Kaddurah-Daouk
Verified email at - Homepage
Cited by
Cited by
Creatine and creatinine metabolism
M Wyss, R Kaddurah-Daouk
Physiological reviews 80 (3), 1107-1213, 2000
Metabolomics: a global biochemical approach to drug response and disease
R Kaddurah-Daouk, BS Kristal, RM Weinshilboum
Annu. Rev. Pharmacol. Toxicol. 48, 653-683, 2008
Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis
P Klivenyi, RJ Ferrante, RT Matthews, MB Bogdanov, AM Klein, ...
Nature medicine 5 (3), 347-350, 1999
Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease
RJ Ferrante, OA Andreassen, BG Jenkins, A Dedeoglu, S Kuemmerle, ...
Journal of Neuroscience 20 (12), 4389-4397, 2000
Metabolomics enables precision medicine:“a white paper, community perspective”
RD Beger, W Dunn, MA Schmidt, SS Gross, JA Kirwan, M Cascante, ...
Metabolomics 12, 1-15, 2016
Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington˘s disease
RT Matthews, L Yang, BG Jenkins, RJ Ferrante, BR Rosen, ...
Journal of Neuroscience 18 (1), 156-163, 1998
The metabolomics standards initiative (MSI)
O Fiehn, D Robertson, J Griffin, M van der Werf, B Nikolau, N Morrison, ...
Metabolomics 3, 175-178, 2007
Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—an emerging role for gut microbiome
S MahmoudianDehkordi, M Arnold, K Nho, S Ahmad, W Jia, G Xie, ...
Alzheimer's & Dementia 15 (1), 76-92, 2019
Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics
X Han, S Rozen, SH Boyle, C Hellegers, H Cheng, JR Burke, ...
PloS one 6 (7), e21643, 2011
Creatine and cyclocreatine attenuate MPTP neurotoxicity
RT Matthews, RJ Ferrante, P Klivenyi, L Yang, AM Klein, G Mueller, ...
Experimental neurology 157 (1), 142-149, 1999
Metabolic network failures in Alzheimer's disease: A biochemical road map
JB Toledo, M Arnold, G Kastenmüller, R Chang, RA Baillie, X Han, ...
Alzheimer's & Dementia 13 (9), 965-984, 2017
Brain and blood metabolite signatures of pathology and progression in Alzheimer disease: A targeted metabolomics study
VR Varma, AM Oommen, S Varma, R Casanova, Y An, RM Andrews, ...
PLoS medicine 15 (1), e1002482, 2018
Metabolomics tools for identifying biomarkers for neuropsychiatric diseases
MP Quinones, R Kaddurah-Daouk
Neurobiology of disease 35 (2), 165-176, 2009
The metabolomics standards initiative
Nature biotechnology 25 (8), 846-848, 2007
Metabolomics: a global biochemical approach to the study of central nervous system diseases
R Kaddurah-Daouk, K Krishnan
Neuropsychopharmacology 34 (1), 173-186, 2009
Metabolomic mapping of atypical antipsychotic effects in schizophrenia
R Kaddurah-Daouk, J McEvoy, RA Baillie, D Lee, JK Yao, ...
Molecular psychiatry 12 (10), 934-945, 2007
Genetic studies of quantitative MCI and AD phenotypes in ADNI: progress, opportunities, and plans
AJ Saykin, L Shen, X Yao, S Kim, K Nho, SL Risacher, VK Ramanan, ...
Alzheimer's & Dementia 11 (7), 792-814, 2015
Standardizing the experimental conditions for using urine in NMR-based metabolomic studies with a particular focus on diagnostic studies: a review
AH Emwas, C Luchinat, P Turano, L Tenori, R Roy, RM Salek, D Ryan, ...
Metabolomics 11, 872-894, 2015
Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: relationship to neuroimaging and CSF biomarkers
K Nho, A Kueider-Paisley, S MahmoudianDehkordi, M Arnold, ...
Alzheimer's & Dementia 15 (2), 232-244, 2019
Enteric microbiome metabolites correlate with response to simvastatin treatment
R Kaddurah-Daouk, RA Baillie, H Zhu, ZB Zeng, MM Wiest, UT Nguyen, ...
PLoS One 6 (10), e25482, 2011
The system can't perform the operation now. Try again later.
Articles 1–20